ライフサイエンスコーパス: capecitabine

1 133 underwent chemoradiotherapy (54 Gy plus capecitabine).

2 b-capecitabine, and 269 received trastuzumab-capecitabine).

3 placebo, in combination with trastuzumab and capecitabine.

4 cells than plasma from mice treated with LDM capecitabine.

5 apeutic limitations of MTD compared with LDM capecitabine.

6 r prevention of HFS in patients treated with capecitabine.

7 (1,000 mg/m(2) twice daily) or placebo plus capecitabine.

8 eiving lapatinib-capecitabine or trastuzumab-capecitabine.

9 rates were 11.0% for eribulin and 11.5% for capecitabine.

10 HFS over the first 6 weeks of treatment with capecitabine.

11 vival with less toxicity than lapatinib plus capecitabine.

12 ntly compared with a similar regimen without capecitabine.

13 odysesthesia were higher with lapatinib plus capecitabine.

14 mab and a taxane, to T-DM1 or lapatinib plus capecitabine.

15 placebo, in combination with trastuzumab and capecitabine.

16 QoL compared with 69 of 123 (56%) receiving capecitabine.

17 val (RFS) and overall survival compared with capecitabine.

18 rmine sample size and test noninferiority of capecitabine.

19 acil or cyclophosphamide and doxorubicin) or capecitabine.

20 -5) was permitted in patients unable to take capecitabine.

21 icin and per-protocol analysis of CMF versus capecitabine.

22 ent of grade 2 or higher HFS or cessation of capecitabine.

23 eive gemcitabine and 364 to gemcitabine plus capecitabine.

24 le with no effect on the pharmacokinetics of capecitabine.

25 LOX, as oxaliplatin 130 mg/m(2) on day 1 and capecitabine 1,000 mg/m(2) twice daily on days 1 to 14 e

26 hibitor ruxolitinib (15 mg twice daily) plus capecitabine (1,000 mg/m(2) twice daily) or placebo plus

27 ), respectively, x four cycles), followed by capecitabine (1,250 mg/m(2) twice a day on days 1 to 14,

28 to 14) every 21 days followed by concurrent capecitabine (1,330 mg/m(2) per day) and radiotherapy (4

29 0 mg/m(2) intravenously on days 1 and 8) and capecitabine (1,500 mg/m(2) per day on days 1 to 14) eve

30 g/m(2) and oxaliplatin 100 mg/m(2) on day 1, capecitabine 1000 mg/m(2) per day on days 1-21, and pani

31 /kg intravenously every 3 weeks) or control (capecitabine 1000 mg/m(2) self-administered orally twice

32 administered intravenously over 2 h and oral capecitabine 1000 mg/m(2) twice daily on days 1-14 repea

33 130 mg/m(2) intravenously over 2 h and oral capecitabine 1000 mg/m(2) twice daily on days 1-14 repea

34 iplatin (oxaliplatin 130 mg/m2 on day 1 with capecitabine 1000 mg/m2 twice daily for 14 days every 3

35 Treatment consisted of capecitabine (1000 mg/m(2) orally twice a day on days 1-

36 isplatin (80 mg/m(2), on the first day) plus capecitabine (1000 mg/m(2), twice daily for 14 days), ev

37 (2) and oxaliplatin 130 mg/m(2) on day 1 and capecitabine 1250 mg/m(2) per day on days 1-21) or modif

38 cycle) or four 3-week cycles of 2500 mg/m(2) capecitabine (1250 mg/m(2) given twice daily on days 1-1

39 s were randomly assigned 1:1 to receive oral capecitabine (1250 mg/m(2) twice daily on days 1-14 of a

40 sion, and 12 weeks of postoperative adjuvant capecitabine (1250 mg/m2 twice daily for 14 days every 3

41 tin [60 mg/m(2)] intravenously on day 1, and capecitabine [1250 mg/m(2)] daily throughout the four cy

42 ib-capecitabine (lapatinib 1,250 mg per day; capecitabine 2,000 mg/m(2) per day on days 1 to 14 every

43 wed by an infusion of 6 mg/kg every 3 weeks; capecitabine 2,500 mg/m(2) per day on days 1 to 14 every

44 zed phase III trial comparing sunitinib plus capecitabine (2,000 mg/m2) with single-agent capecitabin

45 capecitabine (2,000 mg/m2) with single-agent capecitabine (2,500 mg/m2) in patients with heavily pret

46 enously; cisplatin 60 mg/m(2) intravenously; capecitabine 625 mg/m(2) orally twice daily) in 21-day c

47 cisplatin 60 mg/m(2) intravenously on day 1, capecitabine 625 mg/m(2) twice a day orally on days 1-21

48 onsisted of cisplatin 60 mg/m(2) (day 1) and capecitabine 625 mg/m(2) twice daily (days 1-21) for fou

49 taxel (75 mg per square meter on day 1) plus capecitabine (825 mg per square meter twice a day on day

50 cetaxel alone (100 mg/m(2)) with addition of capecitabine (825 mg/m(2) oral twice daily days 1-14, 75

51 Enrolled patients received capecitabine (825 mg/m(2) orally twice daily) with radio

52 0 mg/m(2) once per week for 5 weeks) or oral capecitabine (825 mg/m(2) twice per day, 5 days per week

53 0.4 Gy delivered in 28 daily fractions) with capecitabine (825 mg/m2 orally twice daily) prior to pan

54 chemoradiotherapy (54 Gy over 6 weeks) with capecitabine (825 mg/m2 twice daily), total mesorectal e

55 ravenous infusion, at days 1, 8, and 15) and capecitabine (830 mg/m(2) orally twice daily for 21 days

56 r gemcitabine (300 mg/m(2) once per week) or capecitabine (830 mg/m(2) twice daily, Monday to Friday

57 m(2) on days 1, 8, 15 of a 28-day cycle] and capecitabine [830 mg/m(2) twice daily on days 1-21 of a

58 (PFS); and substitution of fluorouracil with capecitabine ([A vs C] + [B vs D]), assessed by change f

59 al showed that the combination of CB-839 and capecitabine, a prodrug of 5-FU, was well tolerated at b

60 efore random assignment, investigators chose capecitabine, a taxane (paclitaxel, nab-paclitaxel, or d

61 weeks (one cycle) or with 1660 mg/m(2) oral capecitabine administered for 21 days followed by 7 days

62 Capecitabine administration with docetaxel, epirubicin,

63 OMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemotherapy i

64 e combination chemotherapy (oxaliplatin plus capecitabine) after the diagnosis of new liver and lung

65 (1:1) to receive eight 3-week cycles of oral capecitabine alone (1250 mg/m(2) twice daily for 14 days

66 with bevacizumab and capecitabine than with capecitabine alone (median 9.1 months [95% CI 7.3-11.4]

67 rious adverse events were reported (221 with capecitabine alone and 350 with capecitabine and bevaciz

68 as being related to treatment, eight in the capecitabine alone group and 15 in the capecitabine and

69 of whom 1941 had assessable data (968 in the capecitabine alone group and 973 in the capecitabine and

70 hand-foot syndrome (201 [21%] of 963 in the capecitabine alone group vs 257 [27%] of 959 in the cape

71 bevacizumab group vs 78.4%, 75.7-80.9 in the capecitabine alone group; hazard ratio 1.06, 95% CI 0.89

72 bevacizumab plus capecitabine compared with capecitabine alone in elderly patients with metastatic c

73 asal phenotype seemed to obtain benefit with capecitabine, although this will require additional vali

74 p, standard chemotherapy remains superior to capecitabine among hormone receptor-negative patients (H

75 afety and tolerability of the combination of capecitabine and (131)I-huA33.

76 tuzumab emtansine, 254 (51%) of 495 received capecitabine and 241 [49%] of 495 received lapatinib (se

77 was 3% (eight of 251 patients) for lapatinib-capecitabine and 5% (12 of 250 patients) for trastuzumab

78 ved disease-free survival with postoperative capecitabine and ado-trastuzumab emtansine in patients w

79 n the groups (75.4%, 95% CI 72.5-78.0 in the capecitabine and bevacizumab group vs 78.4%, 75.7-80.9 i

80 abine alone group vs 257 [27%] of 959 in the capecitabine and bevacizumab group) and diarrhoea (102 [

81 the capecitabine alone group and 973 in the capecitabine and bevacizumab group).

82 n the capecitabine alone group and 15 in the capecitabine and bevacizumab group.

83 ed (221 with capecitabine alone and 350 with capecitabine and bevacizumab).

84 We investigated whether capecitabine and docetaxel followed by fluorouracil, epi

85 Bevacizumab and the antimetabolites capecitabine and gemcitabine have been shown to improve

86 Both capecitabine and gemcitabine were associated with increa

87 d to either trastuzumab emtansine (n=495) or capecitabine and lapatinib (control; n=496).

88 n, and oxaliplatin (FOLFOX) every 2 weeks or capecitabine and oxaliplatin (CAPOX) in different doses

89 al fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (FOLFOX/CAPOX) with or with

90 Patients received 12 weeks of neoadjuvant capecitabine and oxaliplatin (oxaliplatin 130 mg/m2 on d

91 fluorouracil, leucovorin, and oxaliplatin or capecitabine and oxaliplatin therapy (3 v 6 months) was

92 APOX50 (50-Gy RT for 5 weeks with concurrent capecitabine and oxaliplatin).

93 e cell cycle phase-specific cytotoxic drugs, capecitabine and paclitaxel.

94 TR) = 1.26, 95% CI: 1.02-1.57, P = 0.035) or capecitabine and radiation (TR = 1.25, 95% CI: 1.04-1.51

95 INTERPRETATION: Veliparib plus capecitabine and radiotherapy had an acceptable safety p

96 d recommended phase 2 dose of veliparib plus capecitabine and radiotherapy, with an exposure-adjusted

97 dose of veliparib combined with neoadjuvant capecitabine and radiotherapy.

98 is inhibitor; and cytotoxic regimens such as capecitabine and temozolomide.

99 f 267 patients) of patients in the lapatinib-capecitabine and trastuzumab-capecitabine arms, respecti

100 no difference was detected between lapatinb-capecitabine and trastuzumab-capecitabine for the incide

101 The addition of vemurafenib to capecitabine and/or bevacizumab, cetuximab and/or irinot

102 treated with an anthracycline, a taxane, and capecitabine (and two to five previous regimens for adva

103 40 enrolled patients (271 received lapatinib-capecitabine, and 269 received trastuzumab-capecitabine)

104 mab combined with epirubicin, cisplatin, and capecitabine, and to assess potential biomarkers, in pat

105 therapy combination containing fluorouracil, capecitabine, and/or irinotecan were randomly assigned t

106 (95% CI, 4.5 to 6.0) for the sunitinib plus capecitabine arm and 5.9 months (95% CI, 5.4 to 7.6) for

107 n the lapatinib-capecitabine and trastuzumab-capecitabine arms, respectively.

108 ere randomly assigned to receive eribulin or capecitabine as their first-, second-, or third-line che

109 c toxicity decreased (P = .008), whereas for capecitabine, as CrCl increased, the odds of experiencin

110 fractions over 5 weeks with concurrent oral capecitabine at 650 mg/m(2) twice per day continuously d

111 re randomly assigned to 5 weeks preoperative capecitabine-based chemoradiation (45-50.4 Gy) followed

112 The addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative adju

113 the addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative cape

114 nd feasibility of both gemcitabine-based and capecitabine-based chemoradiotherapy after induction che

115 Our results suggest that a capecitabine-based regimen might be preferable to a gemc

116 n and fluorouracil, and was also similar for capecitabine-based regimens versus leucovorin and fluoro

117 2 periods: p1, during first-line maintenance capecitabine + bevacizumab or observation until the firs

118 -50.4 Gy) followed by six cycles of adjuvant capecitabine, both without (control arm, 1) or with (exp

119 nitoring system (MEMS) caps on participants' capecitabine bottles to record pill bottle openings.

120 ion, for which gemcitabine, fluorouracil, or capecitabine can be used as concurrent chemotherapy agen

121 ivity and per-protocol analyses suggest that capecitabine can improve overall survival in patients wi

122 ugs containing both camptothecin (CPT) and a capecitabine (Cap) analogue.

123 plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorecta

124 Capecitabine (CAP) is a 5-FU pro-drug approved for the t

125 efore random assignment, investigators chose capecitabine (Cape; 2,000 mg/m(2) for 14 days), taxane (

126 cycles of cyclophosphamide, epirubicin, and capecitabine (CEX; n = 753) or three cycles of docetaxel

127 After 12 weeks of induction gemcitabine and capecitabine chemotherapy (three cycles of gemcitabine [

128 o receive a further cycle of gemcitabine and capecitabine chemotherapy followed by either gemcitabine

129 iary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months.

130 0 patients scheduled to receive single-agent capecitabine chemotherapy for breast, colorectal, and ot

131 th peri-operative epiribicin, cisplatin, and capecitabine chemotherapy for patients with resectable g

132 ve peri-operative epirubicin, cisplatin, and capecitabine chemotherapy or chemotherapy plus bevacizum

133 erative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m(2) epirubicin and 60

134 d mitoxantrone, but not that of gemcitabine, capecitabine, cisplatin or oxaliplatin.

135 d mitoxantrone, but not that of gemcitabine, capecitabine, cisplatin, or oxaliplatin.

136 the efficacy and safety of bevacizumab plus capecitabine compared with capecitabine alone in elderly

137 e the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for r

138 alent relapse-free and overall survival with capecitabine compared with standard chemotherapy.

139 able survival outcomes when treated with the capecitabine-containing regimen in an exploratory subgro

140 However, capecitabine could be used in place of CMF without signi

141 suggest that the combination of CB-839 with capecitabine could serve as an effective treatment for P

142 Replacement of fluorouracil with capecitabine did not improve global QoL: 69 of 124 (56%)

143 Capecitabine did not improve QoL compared with fluoroura

144 The addition of sunitinib to capecitabine does not improve the clinical outcome of pa

145 t of HFS greater than grade 1, evaluation of capecitabine dose intensity, and quality of life analyse

146 Capecitabine dose intensity, time under study, and perce

147 the addition of tucatinib to trastuzumab and capecitabine doubled ORR-IC, reduced risk of intracrania

148 mab combined with epirubicin, cisplatin, and capecitabine (ECX) in patients with advanced gastric or

149 or four cycles of epirubicin, cisplatin, and capecitabine (ECX; four 3-weekly cycles of epirubicin [5

150 However, lapatinib-capecitabine efficacy may have been affected by previous

151 panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagoga

152 nt chemotherapy TPC (21-day cycles of either capecitabine, eribulin or vinorelbine).

153 or for standard adjuvant chemotherapy versus capecitabine, especially in patients with hormone recept

154 capecitabine); leucovorin and fluorouracil; capecitabine; FOLFOX-4 (leucovorin, fluorouracil, and ox

155 her half received 3 cycles of docetaxel plus capecitabine followed by 3 cycles of cyclophosphamide, e

156 ent due to vascular disorder (docetaxel plus capecitabine followed by doxorubicin plus cyclophosphami

157 phamide group), sudden death (docetaxel plus capecitabine followed by doxorubicin plus cyclophosphami

158 lled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human ep

159 lowed dosing adjustments of methotrexate and capecitabine for pretreatment renal function.

160 etween lapatinb-capecitabine and trastuzumab-capecitabine for the incidence of CNS metastases.

161 inotecan) and ECX (epirubicin, cisplatin,and capecitabine) for AGC from the cost-effectiveness perspe

162 cancer-specific survival tended to favor the capecitabine group (HR, 0.79; 95% CI, 0.60-1.04; P = .10

163 al was 12.0 months (95% CI 10.2-14.6) in the capecitabine group and 10.4 months (95% CI 8.9-12.5) in

164 al was 15.2 months (95% CI 13.9-19.2) in the capecitabine group and 13.4 months (95% CI 11.0-15.7) in

165 al was 25.9 months (95% CI 19.8-46.3) in the capecitabine group and 17.4 months (12.0-23.7) in the ob

166 al was 24.4 months (95% CI 18.6-35.9) in the capecitabine group and 17.5 months (12.0-23.8) in the ob

167 le patients (62.9%, 80% CI 50.6-73.9) in the capecitabine group and 18 of 35 assessable patients (51.

168 observed in 47 (21%) of 223 patients in the capecitabine group and 22 (10%) of 224 patients in the o

169 d per-protocol analysis (210 patients in the capecitabine group and 220 in the observation group), me

170 urative intent were randomly assigned to the capecitabine group and 224 to the observation group.

171 53 months (95% CI 40 to not reached) in the capecitabine group and 36 months (30-44) in the observat

172 survival was 79.2% (95% CI 61.1-89.5) in the capecitabine group and 64.2 (95% CI 46.4-77.5) in the ge

173 al was 51.1 months (95% CI 34.6-59.1) in the capecitabine group compared with 36.4 months (29.7-44.5)

174 226 of 359 patients in the gemcitabine plus capecitabine group compared with 481 grade 3-4 adverse e

175 Eight patients in the capecitabine group had an objective response at 26 weeks

176 atients in the gemcitabine group than in the capecitabine group had grade 3-4 haematological toxic ef

177 Adverse events were measured in the capecitabine group only, and of the 213 patients who rec

178 Two patients in the capecitabine group progressed during the fourth cycle of

179 urvival for patients in the gemcitabine plus capecitabine group was 28.0 months (95% CI 23.5-31.5) co

180 Of the 34 patients in the capecitabine group who received chemoradiotherapy, 25 (7

181 d (38 to the gemcitabine group and 36 to the capecitabine group).

182 in the combination group and 30 (22%) in the capecitabine group, and treatment-related serious advers

183 nts in the combination group and four in the capecitabine group.

184 A); oxaliplatin and fluorouracil (group B); capecitabine (group C); or oxaliplatin and capecitabine

185 ; capecitabine (group C); or oxaliplatin and capecitabine (group D).

186 nts free from TTR events between the CMF and capecitabine groups (HR 0.98, 95% CI 0.85-1.14; stratifi

187 y more patients taking CMF than those taking capecitabine had clinically relevant worsening of qualit

188 chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function

189 chanistic synergy between nab-paclitaxel and capecitabine has been cited as the rationale to combine

190 th trastuzumab-capecitabine versus lapatinib-capecitabine (hazard ratio [HR] for PFS, 1.30; 95% CI, 1

191 T-DM1 versus 6.4 months with lapatinib plus capecitabine (hazard ratio for progression or death from

192 We aimed to determine whether adjuvant capecitabine improved overall survival compared with obs

193 Addition of sorafenib to capecitabine improved PFS in patients with HER2-negative

194 The addition of oxaliplatin to capecitabine improves DFS in patients with stage III col

195 abine-based chemoradiation and postoperative capecitabine improves disease-free survival (DFS) in loc

196 n and fluorouracil versus those who received capecitabine in adjusted analyses (hazard ratio [HR] 1.0

197 etuximab in combination with oxaliplatin and capecitabine in first-line chemotherapy in patients with

198 Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survi

199 vival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced bre

200 III randomized trial compared eribulin with capecitabine in patients with locally advanced or metast

201 The addition of bevacizumab to capecitabine in the adjuvant setting for colorectal canc

202 better outcome was observed with trastuzumab-capecitabine in the overall population.

203 /methotrexate/fluorouracil over single-agent capecitabine in the treatment of patients age >/= 65 wit

204 profile is manageable, supporting the use of capecitabine in this setting.

205 ur recurrence (TTR); and whether use of oral capecitabine instead of cyclophosphamide would be non-in

206 vant trial to investigate the integration of capecitabine into a regimen of epirubicin and docetaxel

207 Integration of capecitabine into a regimen that contains docetaxel, epi

208 It is not known whether integration of capecitabine into an adjuvant regimen that contains a ta

209 Neratinib plus capecitabine is active against refractory, HER2-positive

210 Capecitabine is an active agent in the treatment of brea

211 Capecitabine is an active drug in metastatic breast canc

212 The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen

213 Capecitabine is not considered a standard agent in the a

214 The doublet regimen of gemcitabine and capecitabine is preferred in the absence of concerns for

215 randomly assigned (1:1) to receive lapatinib-capecitabine (lapatinib 1,250 mg per day; capecitabine 2

216 in our analyses were: XELOX (oxaliplatin and capecitabine); leucovorin and fluorouracil; capecitabine

217 s, while it should be noted that the dose of capecitabine may also be determined by institutional and

218 and 5.9 months (95% CI, 5.4 to 7.6) for the capecitabine monotherapy arm (hazard ratio, 1.22; 95% CI

219 A panel of genetic biomarkers for capecitabine monotherapy toxicity would currently compri

220 venty-six patients were randomly assigned to capecitabine (n = 448) or observation (n = 428).

221 Median OS times for eribulin (n = 554) and capecitabine (n = 548) were 15.9 and 14.5 months, respec

222 assigned to receive either bevacizumab plus capecitabine (n=140) or capecitabine only (n=140).

223 Neither capecitabine nor gemcitabine increased disease-free surv

224 In univariate analysis, the starting dose of capecitabine (odds ratio [OR], 1.99; 95% CI, 1.32-3.00;

225 (2) cisplatin on day 1 and 1250 mg/m(2) oral capecitabine on days 1-21.

226 To investigate the effect of capecitabine on long-term survival outcomes of patients

227 her bevacizumab plus capecitabine (n=140) or capecitabine only (n=140).

228 at precludes other regimens; the addition of capecitabine or erlotinib may be offered.

229 3 x 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by dox

230 The addition of capecitabine or gemcitabine to docetaxel therapy, as com

231 al were to determine whether the addition of capecitabine or gemcitabine to neoadjuvant chemotherapy

232 The choice of fluoropyrimidine therapy (capecitabine or infused fluouroracil plus leucovorin) wa

233 the existing evidence that oxaliplatin plus capecitabine or leucovorin and fluorouracil is the stand

234 of whether the fluoropyrimidine backbone was capecitabine or leucovorin and fluorouracil.

235 y, patients were randomly assigned to either capecitabine or observation.

236 metastatic breast cancer receiving lapatinib-capecitabine or trastuzumab-capecitabine.

237 CAP45 (45-Gy RT for 5 weeks with concurrent capecitabine) or CAPOX50 (50-Gy RT for 5 weeks with conc

238 reated with fluoropyrimidines (fluorouracil, capecitabine, or tegafur-uracil as single agents, in com

239 Neoadjuvant chemoradiotherapy consisted of capecitabine (original dose 825 mg/m(2) twice daily on d

240 progression of disease (PD1); and p2, during capecitabine + oxaliplatin + bevacizumab or another rein

241 d the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP

242 T-DM1 (43.6%, vs. 30.8% with lapatinib plus capecitabine; P<0.001); results for all additional secon

243 cs were dose proportional, with no effect on capecitabine pharmacokinetics.

244 ) or placebo plus epirubicin, cisplatin, and capecitabine (placebo group; n=305).

245 reak for 7 days) or the same regimen of oral capecitabine plus 16 cycles of 7.5 mg/kg bevacizumab by

246 zumab emtansine (233 [48%] of 490) than with capecitabine plus lapatinib control treatment (291 [60%]

247 safety population (488 patients treated with capecitabine plus lapatinib, 490 patients treated with t

248 This multicenter, randomized trial compared capecitabine plus oxaliplatin (XELOX) with bolus fluorou

249 aging were identified between the CVI FU and capecitabine regimens or between the two regimens with o

250 osphamide/methotrexate/fluorouracil, AC, and capecitabine, respectively.

251 The addition of sorafenib to capecitabine resulted in a significant improvement in PF

252 astases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free surviva

253 rilotumumab plus epirubicin, cisplatin, and capecitabine (rilotumumab group; n=304) or placebo plus

254 The adjuvant combination of gemcitabine and capecitabine should be the new standard of care followin

255 as significantly longer with bevacizumab and capecitabine than with capecitabine alone (median 9.1 mo

256 s 70/221 [32%]; p=0.17), but was higher with capecitabine than with fluorouracil (88/222 [40%] vs 65/

257 val and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or

258 verse events were higher with lapatinib plus capecitabine than with T-DM1 (57% vs. 41%).

259 ts treated with standard chemotherapy versus capecitabine, the RFS rates were 56% and 50%, respective

260 we characterized the effects of LDM and MTD capecitabine therapy on tumor and host cells using high-

261 this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epiru

262 The addition of gemcitabine or capecitabine to neoadjuvant docetaxel plus doxorubicin p

263 gnificant increase in DFS by adding extended capecitabine to standard chemotherapy in patients with e

264 used radiolabeled huA33 in combination with capecitabine to target chemoradiation to metastatic colo

265 Global capecitabine toxicity (grades 0/1/2 v grades 3/4/5) was

266 n days 1 to 14 every 21 days) or trastuzumab-capecitabine (trastuzumab loading dose of 8 mg/kg follow

267 Plasma from MTD capecitabine-treated mice induced a more tumorigenic and

268 n NK and T cytotoxic cells were found in MTD-capecitabine-treated tumors compared with LDM-capecitbin

269 Capecitabine treatment was associated with less nausea,

270 uality of life (QoL) substudy tested whether capecitabine treatment would be associated with a better

271 stratified by geographical region, previous capecitabine treatment, and human epidermal growth facto

272 syndrome (HFS) is a common adverse effect of capecitabine treatment.

273 and 5% (12 of 250 patients) for trastuzumab-capecitabine (treatment differences, -1.6%; 95% CI, -2%

274 ) of cisplatin on day 1, 850 mg/m(2) of oral capecitabine twice a day for 2 weeks followed by 1 week

275 receive either three cycles of docetaxel and capecitabine (TX) followed by three cycles of cyclophosp

276 cycles of cyclophosphamide, epirubicin, and capecitabine (TX+CEX).

277 l in 1122 patients treated with single-agent capecitabine using slides prepared in Norway.

278 PFS and OS were longer with trastuzumab-capecitabine versus lapatinib-capecitabine (hazard ratio

279 DFS was not significantly prolonged with capecitabine versus observation [hazard ratio (HR), 0.82

280 Tolerance of capecitabine was as expected, with 75.2% of patients com

281 Although capecitabine was associated with better QoL during treat

282 y a single-therapy infusion 1 wk later, when capecitabine was commenced.

283 Ruxolitinib plus capecitabine was generally well tolerated and may improv

284 ease, where the therapeutic advantage of MTD capecitabine was limited despite a substantial initial a

285 d adjuvant chemotherapy with oxaliplatin and capecitabine was recommended.

286 events during chemoradiotherapy, the dose of capecitabine was reduced to 725 mg/m(2) twice-daily, 5 d

287 s warranted further therapy and temozolomide-capecitabine was started with morphological and biochemi

288 Median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, respectively (HR,

289 with GI tumors or breast cancer treated with capecitabine were included in this randomized phase III

290 eceived RCT (45-50 Gy with 5-fluorouracil or capecitabine) were included and randomized into a 7- or

291 ceived RCT (45 to 50 Gy with fluorouracil or capecitabine) were included.

292 eemed to derive benefit from the addition of capecitabine with a DFS HR of 0.53 versus 0.94 in those

293 d random assignment (R-C) compared docetaxel-capecitabine with an anthracycline-based regimen.

294 nation chemotherapy compared gemcitabine and capecitabine with gemcitabine monotherapy in 730 evaluab

295 lapse survival was also compared between the capecitabine with or without oxaliplatin and leucovorin

296 ival between the patient groups who received capecitabine with or without oxaliplatin and those who r

297 Adjuvant capecitabine with or without oxaliplatin versus leucovor

298 Administering capecitabine with preoperative RT achieved similar rates

299 dy, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.

300 r placebo daily for a maximum of 8 cycles of capecitabine, with stratification by sex and use in adju